Search Results

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced its participation in the Jefferies Healthcare Conference in New York on June 5-6, 2024.

BioArctic AB’s partner Eisai said that they expect Leqembi sales to total JPY 56.5 billion for their fiscal year 2024.

According to Vision Research Reports, the global pyrogen testing market size was estimated at around USD 1.32 billion in 2023 and it is expected to grow at a CAGR of 8.56% from 2024 to 2033, to reach around USD 3 billion by 2033.

Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $56 million financing.

PacBio announced preliminary unaudited revenue for the fourth quarter 2023 and full year 2023 of $58.4 million and $200.5 million representing year-over-year growth of 113% and 56%, respectively.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases and macular degenerations, today announced presentations at The Retina Society 56th Annual Scientific Meeting taking place in New York, New York from October 11-14, 2023.

Hyku Biosciences, Inc. (Hyku) today announced its launch with $56 million in seed financing to develop precision covalent medicines in oncology.

Today, Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals has announced an oversubscribed $56 million Series A funding round led by Eclipse and GE HealthCare with participation from Echo Global, Fox Chase Cancer Center, Granger Management, Mayo Clinic, Mercy Health, and University of Missouri.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial were presented at The Retina Society 56th Annual Scientific Meeting.